Investigator
Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino and Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy, Italy
Dr. Mattia D’Agostino is assistant professor of Hematology at the University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Italy. He studied Medicine at the Vita-Salute San Raffaele University (Milan, Italy, 2008-2014) and completed his residency in Hematology at the University of Torino (2015-2019). In 2019, he was awarded a six-month fellowship at the Massachusetts General Hospital (Boston, MA, Harvard medical school affiliate) under the mentorship of Prof. Noopur Raje.
Dr. D’Agostino is involved in the design, development, and coordination of phase I/II/III clinical trials for the treatment of multiple myeloma in tight collaboration with the European Myeloma Network (EMN, EMN Italy Foundation). He is currently an investigator in several multi-center clinical trials. He is a member of SIE, EMN, and IMS and author of several papers published in peer reviewed journals, including the Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma (JCO, 2022).
Dr. D’Agostino’s main research focuses on the diagnosis and the clinical and experimental treatment of patients with multiple myeloma and associated disorders. He is engaged in clinical and translational research, with a focus on the prognostic evaluation of multiple myeloma and minimal residual disease measurement. The aim of his research is to define risk-adapted approaches in multiple myeloma treatment as an innovative precision medicine approach. His interests also include the use of new biological molecules, monoclonal antibodies, immunotherapeutic agents, CAR T-cell therapy, and stem-cell transplantation techniques.